Fundraising FoxBeta Bionics, Inc
NASDAQ: BBNXIrvine, US · Founded 2015 · Delaware corporation · 5 known investors
Find your way into Beta Bionics, Inc
Sign up to see every warm intro you have to Beta Bionics, Inc
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Beta Bionics, Inc team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Beta Bionics develops the iLet Bionic Pancreas System, an insulin delivery device for people with type 1 diabetes aged 6 and older that requires a physician's prescription. The company operates in the medical device and diabetes care space.
Founders & leadership
Beta Bionics, Inc was founded in 2015 by Edward Damiano.
ED
Edward DamianoFounder
SS
Sean SaintChief Executive OfficerSean Saint served as an R&D Director at a diabetes medical device company before being diagnosed with Type 1 diabetes in 2011. He is now President, CEO and Director of Beta Bionics, which develops the iLet Bionic Pancreas System for insulin delivery in people with type 1 diabetes.
MM
Mike MensingerChief Product OfficerMike Mensinger held a role in R&D and manufacturing at Companion Medical, where he worked on the InPen smart insulin pen and integrated diabetes management platform for diabetes care. He now serves as Chief Product Officer at Beta Bionics, which develops the iLet Bionic Pancreas System for insulin delivery in type 1 diabetes management.
MH
Mark HopmanChief Commercial OfficerMark Hopman is Chief Commercial Officer at Beta Bionics, which makes the iLet Bionic Pancreas System for type 1 diabetes. He previously spent seven years at Dexcom building the retail pharmacy distribution channel for continuous glucose monitoring, and earlier held roles in pharmacy management and clinical program management at Kroger-affiliated entities.
GC
Gilbert ClarkeNamed on SEC filing
ER
Edward RaskinNamed on SEC filing
MR
Mike RoskinoNamed on SEC filing
AM
Agustin MohedasNamed on SEC filing
JH
Jeff HitchcockNamed on SEC filing
SR
Serafina RaskinNamed on SEC filing
Investors · 5
LifeSci Venture Partnerslisted by LifeSci Venture PartnersNew York
How we know: LifeSci Venture Partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Wellington Managementlisted by Wellington ManagementBoston · $5M – $50M
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
RTW Investments L.P.reportedNew York
How we know: the S-1 prospectus · a partner's Signal profile · Not right? Tell us
Soleus CapitalreportedGreenwich
How we know: the S-1 prospectus · Not right? Tell us
Funding
SEC filings, press & company announcements$337.5M disclosed across 5 of 6 rounds · 2017–2025
- Undisclosed amountinitial public offeringJan 2025Source ↗
▶$99.5MraisedSep 2023 · 29 investors · Other Health CareRule 506(b)
▶$99.5MraisedSep 2023 · 29 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Sean D. CarneyDirector
- Stephen H. FeiderExecutive Officer
- Lennox KetnerDirector
- Francesco DraettaDirector
- Amanda BlackDirector
- Edward DamianoExecutive Officer, Director
- Sean T. SaintExecutive Officer, Director
- Gilad GlickDirector
- Westley DuprayDirector
- Parker CassidyDirector
- Offering amount
- $101.8M
- Amount sold
- $99.5M
- First sale
- Aug 2023
- Incorporated
- Corporation, Massachusetts
- Federal exemptions
- 06b
▶$57MraisedMar 2022 · 21 investors · Other Health CareRule 506(b)
▶$57MraisedMar 2022 · 21 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Edward DamianoDirector
- Gibb ClarkeExecutive Officer
- Sean CarneyDirector
- Marcie CainExecutive Officer
- Finny KuruvillaDirector
- Beth BrookeDirector
- Michael PereiraExecutive Officer
- Veena RaoExecutive Officer
- Martha AronsonExecutive Officer, Director
- Jeff HitchcockDirector
- Christy JonesDirector
- Offering amount
- $57M
- Amount sold
- $57M
- First sale
- Feb 2022
- Incorporated
- Corporation, Massachusetts
- Federal exemptions
- 06b
▶$63.4MraisedJul 2019 · 12 investors · Other Health CareRule 506(b)
▶$63.4MraisedJul 2019 · 12 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Edward DamianoExecutive Officer, Director
- Gilbert ClarkeExecutive Officer
- Edward RaskinExecutive Officer, Director
- Mike RoskinoExecutive Officer
- Agustin MohedasDirector
- Jeff HitchcockDirector
- Serafina RaskinExecutive Officer
- Adam SteensbergDirector
- Offering amount
- $63.4M
- Amount sold
- $63.4M
- First sale
- Jul 2019
- Incorporated
- Corporation, Massachusetts, 2015
- Federal exemptions
- 06b
▶$57.6MraisedOct 2018 · 24 investors · Other Health CareRule 506(b)
▶$57.6MraisedOct 2018 · 24 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey HitchcockDirector
- Deirdre IbsenDirector
- CHRISTIAN FogedDirector
- Edward B. RaskinExecutive Officer, Director
- THOMAS A. FITZGERALDExecutive Officer
- Serafina RaskinExecutive Officer
- Edward R. DamianoExecutive Officer, Director
- Mike RosinkoExecutive Officer
- Martin H LangeDirector
- Gilbert ClarkeExecutive Officer
- Amount sold
- $57.6M
- Minimum investment
- $1
- Sales commissions
- $825K
- Placement agents
- Piper Jaffray & Co.
- First sale
- Dec 2017
- Incorporated
- Corporation, Massachusetts, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
DiabetesA nonprofit organization that provides educational resources and information about prediabetes, including prevention strategies and lifestyle management for Americans at risk of developing type 2 diabetes.
DexComDexcom develops continuous glucose monitoring (CGM) systems and glucose biosensors, including the Dexcom G7 and the over-the-counter Stelo biosensor, that send real-time glucose readings to a phone or receiver. Its products serve people managing diabetes as well as consumers tracking glucose for general health, diet, and exercise.
Companies working in the same space as Beta Bionics, Inc.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Defense Advanced Research Projects Agency (DARPA)Defense Advanced Research Projects Agency | Phase IISTTR | 2020 | $779.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.6M |
| Defense Advanced Research Projects Agency (DARPA)Defense Advanced Research Projects Agency | Phase ISTTR | 2019 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $425K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Beta Bionics, Inc do?
- Beta Bionics develops the iLet Bionic Pancreas System, an insulin delivery device for people with type 1 diabetes aged 6 and older that requires a physician's prescription. The company operates in the medical device and diabetes care space.
- Who founded Beta Bionics, Inc?
- Beta Bionics, Inc was founded by Edward Damiano in 2015.
- Who are Beta Bionics, Inc's investors?
- Beta Bionics, Inc's investors include LifeSci Venture Partners, Wellington Management, Omega Funds, RTW Investments L.P., Soleus Capital.
- How much funding has Beta Bionics, Inc raised?
- Beta Bionics, Inc has disclosed $337.5M raised across 5 of its 6 known rounds.
- Where is Beta Bionics, Inc headquartered?
- Beta Bionics, Inc is headquartered in Irvine, US.